Expert Review of Neurotherapeutics · 2014 · 44 citations · 50 references
Life SciencesBiochemistryNeurologyGene TherapyMitochondrial BiologyNeurodegenerationMitochondrial DiseaseMitochondrial DisordersMitochondrial DysfunctionMitochondrial Neurological DisordersNeurodegenerative DiseasesNeurodegenerative DisordersAtp Synthesis MechanismGene-targeted TherapyMitochondrial AtaxiaMitochondrial Dysfunction TherapeuticsMitochondrial Gene TherapyMitochondrial Iron AccumulationMitochondrial Iron MetabolismMitochondrial Therapy
Friedreich ataxia (FRDA) is an inherited, progressive, neurodegenerative disease for which there is presently no cure or effective therapeutic intervention. While physiologically complex, FRDA is caused by deficits in production and expression of frataxin (FXN), a mitochondrial protein important for regulation of iron-sulfur cluster containing enzymes in the cell. Depletion of FXN is associated with dysfunction of ATP synthesis, mitochondrial iron accumulation, potentially an increase in oxidative stress, and cellular dysfunction. Therapeutic development presently focuses on improving mitochondrial function and increasing FXN expression. Gene therapy, a field which has undergone significant advances in recent years, may offer a promising treatment for FRDA in the future. This collection of approaches provides many possible opportunities for treating this multisystem disorder.
50
Clinical and Genetic Abnormalities in Patients with Friedreich's Ataxia
Alexandra Dürr, Mireille Cossée, Yves Agid et al. · New England Journal of Medicine · 1996 · 1.1K citations · Full text
Life Sciences, Genetics, Neurology +10
PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
Joo‐Ho Shin, Han Seok Ko, Ho Chul Kang et al. · Cell · 2011 · 943 citations · Full text
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia
David Herman, Kai Jenssen, Ryan Burnett et al. · Nature Chemical Biology · 2006 · 435 citations · Full text